Current Liabilities
Accounts Payable
Bristol-Myers Squibb Accounts Payable increased by 18.4% to $4.23B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $4B to $4.23B. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 5.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase can signal improved working capital management, while a sudden decrease might indicate accelerated payments to suppliers.
Detailed definition
This reflects the total amount owed to suppliers and vendors for goods and services received on credit. It serves as a f...
Peer comparison
Pharmaceutical companies generally maintain consistent payable cycles, though these can fluctuate based on supply chain management strategies.
Metric ID:
accounts_payableHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.61B | $2.7B | $2.95B | $2.94B | $2.88B | $2.6B | $3.04B | $3.19B | $3.07B | $2.81B | $3.26B | $3.54B | $3.75B | $3.47B | $3.6B | $4B | $5.43B | $4.29B | $3.58B | $4.23B |
| QoQ Change | — | -25.3% | +9.4% | -0.2% | -2.1% | -10.0% | +17.1% | +5.1% | -3.9% | -8.3% | +15.9% | +8.6% | +6.0% | -7.5% | +3.8% | +11.1% | +35.6% | -21.0% | -16.6% | +18.4% |
| YoY Change | — | — | — | — | -20.1% | -3.7% | +3.1% | +8.5% | +6.5% | +8.4% | +7.2% | +10.8% | +22.2% | +23.3% | +10.5% | +13.1% | +44.7% | +23.6% | -0.7% | +5.8% |
Range$2.6B – $5.43B
CAGR+3.4%
Avg YoY Growth+10.2%
Median YoY Growth+8.4%
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's accounts payable?
- Bristol-Myers Squibb (BMY) reported accounts payable of $4.23B in Q1 2026.
- How has Bristol-Myers Squibb's accounts payable changed year-over-year?
- Bristol-Myers Squibb's accounts payable increased by 5.8% year-over-year, from $4B to $4.23B.
- What is the long-term trend for Bristol-Myers Squibb's accounts payable?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's accounts payable has grown at a 5.7% compound annual growth rate (CAGR), from $2.71B to $3.58B.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services already received.